'Prehab' program boosts fitness of patients with cancer
the ONA take:
Researchers at the University of Southampton have developed a fitness program that speeds recovery for cancer patients, with the goal of returning them to a pre-treatment level of fitness in approximately 6 weeks.
Treatment with chemotherapy or chemoradiotherapy before surgery can reduce the fitness level of patients with cancer. The researchers, led by Professor Mike Grocott, evaluated this decline, and also investigated the effect of specially tailored exercise programs enacted after a patient’s chemotherapy treatment but before surgery.
They discovered that supervised bicycle training, some three times a week, helped to not only prevent the expected fitness decline, but also returned patients to pre-treatment fitness levels within 6 week’s time. Improvements in stay and readmission rates, as well as a decrease in cardiorespiratory complications, were observed. Patients that did not participate experienced the expected fitness level decline.
In previous fitness programs, exercise takes place after the cancer operation or operations; in this case, the individualized exercise programs were purposefully administered before surgery. The researchers termed the process a“prehabilitation” program. Professor Grocott is hopeful that participation in such individualized programs, pre-surgery, could improve outcomes, but further research with a larger sample size is required to prove this theory.
Researchers have developed a fitness program that speeds recovery for cancer patients.
Doctors and scientists in Southampton can return cancer patients to pre-treatment fitness levels within six weeks using a novel 'prehabilitation' programme. Led by Professor Mike Grocott, researchers at the NIHR Southampton Respiratory Biomedical Research Unit studied the effect of tailored exercise programmes on bowel cancer patients after chemotherapy and radiotherapy but before surgery.
In the UK in 2012, more than 9,000 people were diagnosed with the rectal form of bowel cancer and three-quarters underwent major surgery with a death rate of 3.2%.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Immunotherapy and the Future of Prostate Cancer Treatment
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|